Filing summary
Entity mismatch: The supplied filing is ReShape Lifesciences Inc.’s Form 10-Q, not a filing for Vyome Holdings, Inc. It covers the quarter ended March 31, 2023; amounts below are in U.S. dollars, generally thousands unless noted.
Business context and reporting period
ReShape sells the Lap-Band system and offers ReShapeCare and ReShape Marketplace; its Diabetes Bloc-Stim Neuromodulation (DBSN) device remains in development. Lap-Band accounted for nearly all revenue and gross profit. The company reports sales across the United States, Australia, Europe, and the rest of the world.
Key financial results
| Metric | Q1 2023 | Q1 2022 |
|---|---|---|
| Revenue | $2.287 million | $2.440 million |
| Gross profit / margin | $1.224 million / 53.5% | $1.218 million / 49.9% |
| Operating expenses | $6.855 million | $9.331 million |
| Operating loss | $5.631 million | $8.113 million |
| Net loss | $2.662 million | $8.115 million |
| Adjusted EBITDA loss | $5.338 million | $6.817 million |
| Net cash used in operations | $5.061 million | $7.378 million |
The 2023 net loss included a $2.965 million noncash gain from changes in the fair value of warrant liabilities, which reduced the reported loss. Basic and diluted loss per share was $1.56, compared with $21.87 in Q1 2022; share and per-share figures were retroactively adjusted for the December 2022 1-for-50 reverse stock split.
At March 31, 2023, cash and cash equivalents were $8.983 million, restricted cash was $0.100 million, and working capital was approximately $7.6 million. Total liabilities were $8.594 million, including a $0.992 million warrant liability; the filing does not report borrowings or other conventional debt. The company raised $10.201 million net cash from financing during the quarter. Cash, cash equivalents, and restricted cash totaled $9.083 million at quarter-end.
Changes versus the prior period
- Revenue declined 6.3%, principally due to weaker European sales; Europe revenue fell 26.6%. U.S. revenue declined 1.7%.
- Gross margin improved to 53.5% from 49.9%, which management attributed to manufacturing efficiencies and cost reductions.
- Operating expenses fell 26.5%, mainly because sales and marketing expense declined 53.5% after a shift to targeted digital marketing, and research and development expense declined 39.2%. General and administrative expense rose 8.4%, including one-time professional-service costs primarily related to the February offering.
- Operating cash use improved from $7.378 million to $5.061 million. The quarter’s financing proceeds were primarily from the February public offering.
Outlook, risks, and unusual items
- Going concern: The company says revenue does not cover operating costs and that available cash may not fund operations for more than 12 months from the filing date. Management concluded substantial doubt about the company’s ability to continue as a going concern is not alleviated; additional financing may be needed, with no assurance it will be available on acceptable terms.
- Management outlook: Management expects revenue to increase during the remainder of 2023, citing targeted digital marketing near bariatric surgical centers and the launch of three new calibration-tube sizes. Plans also include growing Lap-Band sales, expanding ReShapeCare and Marketplace, continuing DBSN development, and pursuing licensing and portfolio opportunities. The filing gives no numerical revenue or earnings guidance.
- Financing and dilution: The February offering generated approximately $10.2 million gross proceeds and $9.4 million net cash proceeds, before considering cash-flow statement presentation. Warrants issued with the offering were exercisable for shares and were partly exercised through cashless exercise by quarter-end. A subsequent registered direct offering and concurrent private placement closed April 24, 2023, with approximately $2.5 million gross proceeds, additional warrants, and repricing of certain existing warrants.
- Litigation: On May 11, 2023, a court entered judgment for Cowen & Company, including a $1.35 million fee, interest, and $675,000 of attorneys’ fees. ReShape had accrued approximately $2.25 million for the fee, legal costs, and interest at March 31 and paid a first installment of approximately $1.9 million on May 12.
- Internal controls: Management concluded internal control over financial reporting was not effective due to material weaknesses involving staffing and accounting expertise, purchase accounting, income taxes, journal-entry approval, and IT access/change management. Remediation is underway. The filing also refers to prior-period financial statement restatements.
- Other risks: The company cites ongoing operating losses, dependence on future financing and product commercialization, medical-device development and regulatory risks, and international operating effects. It reports no material changes to the risk factors in its 2022 Form 10-K.
Important facts for investors to verify
- Confirm the intended issuer: this filing identifies ReShape Lifesciences Inc. (ticker RSLS), not Vyome Holdings, Inc.
- Assess the company’s runway and financing needs in light of the explicit going-concern warning, continued operating cash burn, and subsequent offering.
- Review the terms, potential share dilution, exercise status, and accounting treatment of the February and April 2023 warrants and securities offerings.
- Track Lap-Band revenue by geography and whether the forecast improvement for the rest of 2023 materializes.
- Monitor payment obligations and any further developments in the Cowen judgment, and confirm the final amounts and schedule.
- Evaluate progress in remediating material weaknesses and the implications of prior-period restatements.